Literature DB >> 27320922

Sustained Elevated Adenosine via ADORA2B Promotes Chronic Pain through Neuro-immune Interaction.

Xia Hu1, Morayo G Adebiyi2, Jialie Luo3, Kaiqi Sun2, Thanh-Thuy T Le4, Yujin Zhang4, Hongyu Wu4, Shushan Zhao4, Harry Karmouty-Quintana4, Hong Liu2, Aji Huang4, Yuan Edward Wen4, Oleg L Zaika5, Mykola Mamenko5, Oleh M Pochynyuk5, Rodney E Kellems2, Holger K Eltzschig6, Michael R Blackburn2, Edgar T Walters5, Dong Huang7, Hongzhen Hu3, Yang Xia8.   

Abstract

The molecular mechanisms of chronic pain are poorly understood and effective mechanism-based treatments are lacking. Here, we report that mice lacking adenosine deaminase (ADA), an enzyme necessary for the breakdown of adenosine, displayed unexpected chronic mechanical and thermal hypersensitivity due to sustained elevated circulating adenosine. Extending from Ada(-/-) mice, we further discovered that prolonged elevated adenosine contributed to chronic pain behaviors in two additional independent animal models: sickle cell disease mice, a model of severe pain with limited treatment, and complete Freund's adjuvant paw-injected mice, a well-accepted inflammatory model of chronic pain. Mechanistically, we revealed that activation of adenosine A2B receptors on myeloid cells caused nociceptor hyperexcitability and promoted chronic pain via soluble IL-6 receptor trans-signaling, and our findings determined that prolonged accumulated circulating adenosine contributes to chronic pain by promoting immune-neuronal interaction and revealed multiple therapeutic targets.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27320922      PMCID: PMC5662192          DOI: 10.1016/j.celrep.2016.05.080

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  63 in total

1.  'Inhibition of IL-6 signaling: a novel therapeutic approach to treating spinal cord injury pain' by Guptarak et al.

Authors:  Cathrine Baastrup; Nanna Brix Finnerup; Andrew S C Rice; Troels Staehelin Jensen; Robert P Yezierski
Journal:  Pain       Date:  2013-10-22       Impact factor: 6.961

2.  Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice.

Authors:  P G Murphy; M S Ramer; L Borthwick; J Gauldie; P M Richardson; M A Bisby
Journal:  Eur J Neurosci       Date:  1999-07       Impact factor: 3.386

3.  Monocytes/Macrophages control resolution of transient inflammatory pain.

Authors:  Hanneke L D M Willemen; Niels Eijkelkamp; Anibal Garza Carbajal; Huijing Wang; Matthias Mack; Jitske Zijlstra; Cobi J Heijnen; Annemieke Kavelaars
Journal:  J Pain       Date:  2014-05       Impact factor: 5.820

4.  Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture.

Authors:  Nanna Goldman; Michael Chen; Takumi Fujita; Qiwu Xu; Weiguo Peng; Wei Liu; Tina K Jensen; Yong Pei; Fushun Wang; Xiaoning Han; Jiang-Fan Chen; Jurgen Schnermann; Takahiro Takano; Lane Bekar; Kim Tieu; Maiken Nedergaard
Journal:  Nat Neurosci       Date:  2010-05-30       Impact factor: 24.884

5.  Mast cell activation contributes to sickle cell pathobiology and pain in mice.

Authors:  Lucile Vincent; Derek Vang; Julia Nguyen; Mihir Gupta; Kathryn Luk; Marna E Ericson; Donald A Simone; Kalpna Gupta
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

6.  Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology.

Authors:  Isaac M Chiu; Christian A von Hehn; Clifford J Woolf
Journal:  Nat Neurosci       Date:  2012-07-26       Impact factor: 24.884

Review 7.  Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense.

Authors:  Edgar T Walters
Journal:  Exp Neurol       Date:  2014-08       Impact factor: 5.330

8.  Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal.

Authors:  K O Aley; P G Green; J D Levine
Journal:  J Neurosci       Date:  1995-12       Impact factor: 6.167

9.  Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2.

Authors:  Catherine Abbadie; Jill A Lindia; Anne Marie Cumiskey; Larry B Peterson; John S Mudgett; Ellen K Bayne; Julie A DeMartino; D Euan MacIntyre; Michael J Forrest
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

10.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Authors:  N Nishimoto; N Miyasaka; K Yamamoto; S Kawai; T Takeuchi; J Azuma
Journal:  Ann Rheum Dis       Date:  2008-11-19       Impact factor: 19.103

View more
  27 in total

1.  Sphingosine-1-phosphate receptor 1 mediates elevated IL-6 signaling to promote chronic inflammation and multitissue damage in sickle cell disease.

Authors:  Shushan Zhao; Morayo G Adebiyi; Yujin Zhang; Jacob P Couturier; Xuegong Fan; Hongqi Zhang; Rodney E Kellems; Dorothy E Lewis; Yang Xia
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

Review 2.  Targeting novel mechanisms of pain in sickle cell disease.

Authors:  Huy Tran; Mihir Gupta; Kalpna Gupta
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

Review 3.  Metabolomic and molecular insights into sickle cell disease and innovative therapies.

Authors:  Morayo G Adebiyi; Jeanne M Manalo; Yang Xia
Journal:  Blood Adv       Date:  2019-04-23

4.  Elevated ecto-5'-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell disease.

Authors:  Hong Liu; Morayo Adebiyi; Rong Rong Liu; Anren Song; Jeanne Manalo; Yuan Edward Wen; Alexander Q Wen; Tingting Weng; Junsuk Ko; Modupe Idowu; Rodney E Kellems; Holger K Eltzschig; Michael R Blackburn; Harinder S Juneja; Yang Xia
Journal:  Blood Adv       Date:  2018-08-14

Review 5.  Targeting novel mechanisms of pain in sickle cell disease.

Authors:  Huy Tran; Mihir Gupta; Kalpna Gupta
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  Pathological overproduction: the bad side of adenosine.

Authors:  Pier Andrea Borea; Stefania Gessi; Stefania Merighi; Fabrizio Vincenzi; Katia Varani
Journal:  Br J Pharmacol       Date:  2017-03-31       Impact factor: 8.739

7.  Circadian period 2: a missing beneficial factor in sickle cell disease by lowering pulmonary inflammation, iron overload, and mortality.

Authors:  Morayo G Adebiyi; Zhaoyang Zhao; Youqiong Ye; Jeanne Manalo; Yue Hong; Cheng Chi Lee; Wa Xian; Frank McKeon; Rachel Culp-Hill; Angelo D' Alessandro; Rodney E Kellems; Seung-Hee Yoo; Leng Han; Yang Xia
Journal:  FASEB J       Date:  2019-06-29       Impact factor: 5.191

8.  Adaptive mechanisms driving maladaptive pain: how chronic ongoing activity in primary nociceptors can enhance evolutionary fitness after severe injury.

Authors:  Edgar T Walters
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-09-23       Impact factor: 6.237

Review 9.  Updated mechanisms underlying sickle cell disease-associated pain.

Authors:  Shibin Du; Corinna Lin; Yuan-Xiang Tao
Journal:  Neurosci Lett       Date:  2019-09-07       Impact factor: 3.046

10.  Granulocyte-colony-stimulating factor (G-CSF) signaling in spinal microglia drives visceral sensitization following colitis.

Authors:  Lilian Basso; Tamia K Lapointe; Mircea Iftinca; Candace Marsters; Morley D Hollenberg; Deborah M Kurrasch; Christophe Altier
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.